



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



Warsaw, 5.01.2024.

## **REQUEST FOR QUOTATION No. 1/FENG-HAN/2024**

In connection with applying for the project „Innovative cell therapy for head and neck cancer” co-financed by European Union Funds under measures of the European Funds for Modern Economy under „SMART track”, Cellis Ltd. request to submit price quotation for:

Phase I of clinical trials - hospital procedures.

### **1. ORDERING PARTY**

Cellis Sp. z o.o. [Ltd.]  
ul. Generała Zajączka 28  
01-510 Warsaw, Poland  
VAT EU: PL5252640606

### **2. THE SUBJECT OF THE ORDER:**

2.1 The subject of the order is:

Phase I of clinical trials - hospital procedures.

**Planned date of starting of the order: March 01, 2027.**

2.2 The above-mentioned order consist of:

Performing hospital procedures in patients with head and neck cancer, with persistent disease or local progression after treatment with chemoradiotherapy or radical radiotherapy without the presence of distant metastases, recruited for a phase I clinical trial, including:

- 1) Intratumor administration of the cellular preparation,
- 2) Patient management (12 patients in total: 4 dose groups of 3 patients each):
  - a) min. 7 patient visits (screening test, 1st application of a cell preparation, +4 days, 2nd application of cell preparation, +4 weeks, +12 weeks, +24 weeks) – performing physical and subjective examinations, imaging tests, laboratory tests,
  - b) max. 4 applications of the cellular preparation (at max. 7-day intervals),
  - c) 6-month follow-up period for progression-free survival,
  - d) 12-month follow-up of overall survival,
- 3) Tumor assessment after 4 days, then after 4 weeks, 3 months (12 weeks), 6 months (24 weeks) after study treatment starts,



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



- 4) Confirmation of the first progression using follow-up imaging (MRI) at least three months after the first examination documenting disease progression (PD), unless the researcher decides to initiate alternative therapeutic interventions,

During the confirmation period, treatment may continue as planned if the patient, in the investigator's judgment, demonstrates demonstrable clinical benefit with minimal and acceptable toxicity.

- 5) Conducting tumor assessment,
- 6) Conducting an assessment of blood flow within the tumor,
- 7) Qualifying tumor response as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD),
- 8) Performing survival update monitoring for each patient until death or for a minimum of 12 months.

The clinical trial will be monitored by an external CRO company (Contract Research Organization).

**The main aim of the study is to assess the safety of local administration of a cellular preparation in patients and to establish the recommended dose (RD) for phase II, taking into account the main endpoint: Occurrence of dose-limiting toxicity (DLT).**

**The final scope of the request for quotation will depend on the development of the project and will result from the current needs of the Ordering Party.**

**The Ordering Party reserves the right to complete the order in any part, and the Contractor is not entitled to any claims in this respect.**

2.3. The subject of the order specified in point 2.1 shall be performed no later than August 31, 2029.

2.4 Under this invitation to tender Ordering Party does not allow partial receipt of tenders or variant offers.

2.5 CPV code:

73100000-3 Research and experimental development services

### **3. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS**

3.1 Contractors participating in the proceedings must fulfil following conditions:



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



1) they must have necessary expertise, experience and technical potential ie.:

a) must have the necessary knowledge and documented experience in performing surgical procedures in patients with head and neck cancer with first recurrence in the last 3 years and in conducting early phase clinical trials - especially phase I, II, First in Human studies - in the recent 3 years,

b) must have the necessary technical potential, including the appropriate:

\*technical resources:

- hospital imaging diagnostic facilities - mandatory with magnetic resonance imaging,
- hospital neurosurgical facilities,
- hospital oncology facilities,
- hospital facilities for laboratory tests,

\*equipment:

- Laminar chamber for clean work to specimen preparation (thawing),
- Freezer -80C,
- Liquid nitrogen container;

2) they must have staff potential specialized in at least the following areas: oncology and surgery;

3) they must be in a business and financial situation that ensure timely and requirement compliant performance of the contract.

4) they must declare readiness to comply with the study protocol, as well as the latest version of the Helsinki Declaration, ICH-GCP and national legal and regulatory conditions.

The statement about fulfilling conditions for participation in the proceedings is attached as Appendix 2 to this Request for Quotation no. 1/FENG-HAN/2024.

3.2 The Contractor may not be personally, or equity related to the Ordering Party.

Equity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contract award procedure, and the Contractor, including in particular:

- a) Being a partner to civil law partnership or commercial law partnership,
- b) Holding at least 10% of shares, if lower threshold does not result from law,
- c) Being a member of a supervisory or management corporate body, a holder of general commercial power of attorney, an authorised representative,



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



- d) Being married to, being in direct consanguinity or affinity, second degree consanguinity or affinity of the second degree collaterally or by adoption or guardianship or being in cohabitation with the Contractor, its legal representative or members of management or supervisory bodies of economic operators competing for the contract award,
- e) being in such a legal or factual relationship with the Contractor that there is a reasonable doubt as to their impartiality or independence in connection with the contract award procedure.

The Bidder is obliged to submit a relevant statement contained in Annex 3 to the Request for Quotation no. 1/FENG-HAN/2024.

3.3 The Ordering Party will assess compliance with the conditions for participation in the proceeding based on the information from Bidder contained in the Bid form and Annexes. Assessment of compliance with the requirement will be made by the method meets / does not meet.

3.4 The Ordering Party before signing the Agreement reserves the right to verification statements of the Bidder (meets / does not meet) about conditions for participation in the proceedings based on the documents confirming the Bidder's statements.

3.5 For the proceeding only offers that meet all the conditions for participation in the proceedings will be allowed.

#### **4. PREPARATION AND SUBMISSION OF OFFERS**

4.1 Each Bidder may submit only one offer.

4.2 Offer should be prepared in the bid form (Appendix 1 to the Request for Quotation no. 1/FENG-HAN/2024). The offer must be initialled and signed by the authorised representative of the Bidder. If the offer would be signed by the person not listed in registered documents of the Contractor, the offer shall be accompanied by the appropriate power of attorney.

4.3 Offer must include all attachments required by the Ordering Party confirmed to be true by the authorised representative of the Bidder.

4.4 Contractor must submit with the offer copy (scan) of relevant Register of Business Activity, applicable to country of residence of Contractor, issued not earlier than three (3) months before the deadline for submission the offer to demonstrate the absence of grounds for exclusion.

4.5 The offer must be submitted by March 6, 2024 (23:59).

4.6 The offer must be submitted via website <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>

4.7 Offers received after deadline or incomplete will not be considered.



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



4.8 The offer should include the validity date (at least 60 days from the submission deadline).

4.9 Submitting the tender means acceptance of the conditions stated therein.

4.10 The Bidder may request the Ordering Party to clarify the content of the request for quotation.

Inquiries can be submitted on the website: <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>. The

Ordering Party shall answer questions that have been received no later than by the end of half of the deadline for submission of tenders, except that the answer should be given at least 2 (two) days before the submission deadline. Answers to questions will be published on the website

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>.

## 5. OFFER EVALUATION CRITERIA

5.1 The Ordering Party will evaluate offer based on the following criteria:

Methods of assessment – according to the formula below:

$$P_i = P_i(C)$$

where:

$P_i$  – the amount of points received

$P_i(C)$  – points for the „Price” criterium

- Criterium „Price” – weight 100%

„Price” criterium will be calculated as follows:

$$P_i(C) = (C_{min} : C_i) \times 100$$

where:

$P_i(C)$  – the number of points given for the „Price” criterium

$C_{min}$  – the lowest price among all valid and non-rejected offers

$C_i$  – the price of the currently evaluated offer

In the “Price” criterium Bidder may obtain 100 points.

5.2 All calculations will be made to two decimal places.

5.3 The most advantageous offer will be considered the one which obtains the highest number of points.



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



5.4 The Ordering Party reserves the right to ask the Bidder about the content of submitted bids, including to supplement missing powers of attorney, statements or documents indicated in the request for quotation (except for the extent to which they are subject to evaluation in the bid evaluation criteria).

**6. ORDER COMPLETION DATE:** 30 months.

## **7. NOTICE OF SELECTION OF THE BEST TENDER**

Information of the results of the proceedings will be published on the website

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>.

## **8. CHANGES IN THE AGREEMENT**

All modification to the agreement, which will be concluded as a result of the proceeding, must be in writing under pain of nullity.

## **9. ADDITIONAL INFORMATION**

9.1 The Ordering Party reserves the right to cancel this procedure at any stage, without providing reasons.

9.2 This request for quotation does not oblige Cellis Sp. z o.o. [Ltd.] to conclude an agreement.

## **10. CONTACT**

Cellis Sp. z o.o. [Ltd.]

ul. Generała Zajączka 28

01-510 Warsaw, Poland

Contact person: Małgorzata Sęktas

Appendices:

Appendix 1 Bid form

Appendix 2 Statement on the compliance with conditions for participation in the proceedings

Appendix 3 Statement concerning personal / capital connections between the Bidder and the Ordering Party.



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



**Appendix 1 BID FORM for Request for Quotation no. 1/FENG-HAN/2024**

*Stamp of the Bidder*

Name \_\_\_\_\_

Address \_\_\_\_\_

Phone no. \_\_\_\_\_

Tax Number \_\_\_\_\_

Contact person: \_\_\_\_\_

e-mail: \_\_\_\_\_

**Ordering Party:**

Cellis Sp. z o.o.

Generała Zajączka 28

01-510 Warsaw, Poland

VAT EU: PL5252640606

According to the Request for Quotation no. 1/FENG-HAN/2024 as a part of the applied for funding project „Innovative cell therapy for head and neck cancer” co-financed by European Union Funds under measures of the European Funds for Modern Economy under „SMART track”, Cellis Ltd., I submit tender:

I offer a net price \_\_\_\_\_ PLN / USD / EUR / OTHER.....\*

(in words \_\_\_\_\_ PLN / USD / EUR / OTHER.....)

and gross price \_\_\_\_\_ PLN/ USD/ EUR/ OTHER .....

(in words \_\_\_\_\_ PLN / USD / EUR / OTHER.....)

\_\_\_\_\_  
\* Confirm by ticking or adding relevant information



European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



1. Detailed calculation of the cost:

Stage No.	Activity	Total cost
1.	Intratumor administration of the cellular preparation.	
2.	Patient management (12 patients in total: 4 dose groups of 3 patients each): <ul style="list-style-type: none"> <li>- min. 7 patient visits (screening test, 1st application of a cell preparation, +4 days, 2nd application of cell preparation, +4 weeks, +12 weeks, +24 weeks) – performing physical and subjective examinations, imaging tests, laboratory tests,</li> <li>- max. 4 applications of the cellular preparation (at max. 7-day intervals),</li> <li>- 6-month follow-up period for progression-free survival,</li> <li>- -12-month follow-up of overall survival.</li> </ul>	
3.	Tumor assessment after 4 days, then after 4 weeks, 3 months (12 weeks), 6 months (24 weeks) after study treatment starts.	
4.	Confirmation of the first progression using follow-up imaging (MRI) at least three months after the first examination documenting disease progression (PD), unless the researcher decides to initiate alternative therapeutic interventions.	
5.	Conducting tumor assessment.	
6.	Conducting an assessment of blood flow within the tumor.	
7.	Qualifying tumor response as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD).	
8.	Performing survival update monitoring for each patient until death or for a minimum of 12 months.	
9.	Other costs	
SUM		

2. The Bidder declares that all costs of the completion the order have been included in the price.

3. The Bidder declares that the offer will be valid for 60 days from the deadline for submission.

4. The Bidder declares that is familiar with request for quotation, accept the conditions stated therein and does not raise any objection to completion the order in accordance with these conditions.

\_\_\_\_\_  
Date and place

\_\_\_\_\_  
Signature of the Bidder /  
Person authorized to act on behalf of the Bidder





European  
Funds



Republic  
of Poland

Co-funded by the  
European Union



**Appendix 2 STATEMENT ON THE COMPLIANCE WITH CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS for Request for Quotation no. 1/FENG-HAN/2024**

Bidder

---

(name and address of the Bidder)

1) The Bidder declares that have:

Statement	YES/NO
a) the necessary knowledge and documented experience in performing surgical procedures in patients with head and neck cancer with first recurrence in the last 3 years.	
b) the necessary knowledge and documented experience in conducting early phase clinical trials - especially phase I, II, First in Human studies - in the recent 3 years.	
c) appropriate technical resources, including:	
- hospital imaging diagnostic facilities with magnetic resonance imaging,	
- hospital neurosurgical facilities,	
- hospital oncology facilities,	
- hospital facilities for laboratory tests.	
d) appropriate equipment, including:	
- Laminar chamber for clean work to specimen preparation (thawing),	
- Freezer -80C,	
- Liquid nitrogen container.	
f) staff potential specialized in at least the following areas: oncology and surgery.	

2) The Bidder declares that is in a business and financial situation that ensure timely and requirement compliant performance of the contract.

3) The Bidder declares its readiness to comply with the test protocol, as well as the latest version of the Helsinki Declaration, ICH-GCP and national legal and regulatory conditions.



**European  
Funds**



**Republic  
of Poland**

**Co-funded by the  
European Union**



4) The Bidder declares that the data contained in the offer are true and adequate.

---

Date and place

---

Signature of the Bidder /  
Person authorized to act on behalf of the Bidder



European  
Funds




Republic  
of Poland

Co-funded by the  
European Union



**Appendix 3 STATEMENT CONCERNING PERSONAL / CAPITAL CONNECTIONS BETWEEN THE BIDDER  
AND THE ORDERING PARTY for Request for Quotation no. 1/FENG-HAN/2024**

(Place) \_\_\_\_\_, date \_\_\_\_\_



Statement concerning personal / capital connections between the Bidder and the Ordering Party

I, undersigned \_\_\_\_\_ declare, that:

Have not any personal or capital connections with the Ordering Party

Equity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contractor selection procedure, and the Contractor, including in particular:

- a) Being a partner to civil law partnership or commercial law partnership,
- b) Holding at least 10% of shares, if lower threshold does not result from law,
- c) Being a member of a supervisory or management corporate body, a holder of general commercial power of attorney, an authorised representative,
- d) Being married to, being in direct consanguinity or affinity, second degree consanguinity or affinity of the second degree collaterally or by adoption or guardianship or being in cohabitation with the Contractor, its legal representative or members of management or supervisory bodies of economic operators competing for the contract award,
- e) Being in such a legal or factual relationship with the Contractor that there is a reasonable doubt as to their impartiality or independence in connection with the contract award procedure.

\_\_\_\_\_  
Place and date

\_\_\_\_\_  
Signature of the Bidder /  
Person authorized to act on behalf of the Bidder